Dufourcq, J. et al., “Molecular assembling of DNA with amphipathic peptides”, FEBS Lett., 1998, vol. 421, No. 1, pp. 7-11. |
Ishihara, T. et al., “Rules for Stand Invasion by Chemically Modified Oligonucleotides”, J. Am. Chem. Soc., 1999, vol. 121, No. 10, pp. 2012-2020. |
Simmons, C. G. et al., “Synthesis and membrane permeability of pna-peptide conjugates”, Bioorganics & Medicinal Chemistry Letters, Dec. 2, 1997, vol. 7, No. 23, pp. 3001-3006. |
Arthur, M., et al., “Glycopeptide resistance in enterocci,” Trends Microbiol, 1996, 4(10), 401-407. |
Baquero, F., “Pneumococcal resistance to β-lactam antibiotics: a global geographic overview,” Microb Drug Reist., 1995, 1(2), 115-120. |
Berge, S.M., et al., “Pharmaceutical salts,” J. Pharm. Sciences, 1977, 66(1), 1-19. |
Bert, F., et al., “Comparitve distribution of resistance patterns and serotypes in pseudomonas aeruginosa isolates from intensive care units and other wards,” J. Antimicrob Chemother, 1996, 37, 809. |
Broome-Smith, et al., “The nucleotide sequences of the ponA and ponB genes encoding penicillin-binding proteins 1A and 1B of Escherichia coli K12,” FEBS, 1985, 147, 437-446. |
Carmelli, Y., et al., “The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci,” Arch Intern. Med., 1999, 159, 2461-2468. |
Chambers, H.F., “Methicillin resistance in staphylococci: Molecular and biochemical basis and clinical implications,” Clin. Microbiol. Rev., 1997, 10(4), 781-791. |
CDR Weekly, Communicable Disease Report, ISSN 1350-9357, Feb. 19, 1999, 9(8), 65-75. |
CDR Review, Communicable Disease Report, ISSN 1350-9349, Nov. 10, 1999, 5(7), R173-R188. |
Cookson, B.D., “Nosocomial antimicrobial resistance surveillance,” J. Hosp. Infec., 1999, 43 (Supplement), S97-S103. |
Costerton, J.W., et al., “Bacterial biofilms in nature and disease,” Ann Rev. Microbiol., 1987, 41, 435-464. |
Davis, J., et al., “Inactivation of antibiotics and the dissemination of resistance genes,” Science, 1994, 264, 375-382. |
Demidov, et al., “Stability of peptide nucleic acids in human serum and cellular extracts,” P.E. Biochem. Pharmacol., 1994, 48(6), 1310-1313. |
Egholm, M., et al., “PNA hybridizes to complementary oligonucleotides obeying the watson-crick hydrogen-bonding rules,” Nature, 1993, 365, 566-568. |
Frimodt-Møller, N., et al., “The mouse pertonitis/sepsis model,” Handbook of Animal Models of Infection, Chap. 14, 1999, 127-136. |
Giwercman, B., et al., “Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed β-lactamase producing strains,” J. Anmtimicrob Chemother, 1990, 26, 247-259. |
Good, Liam, et al., “Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA,” Nature Biotechnology, 1998, 16, 355-358. |
Good, Liam, et al., “Inhibition of translation and bacterial growth by peptide nucleic acid targeted to ribosomal RNA,” Proc. Natl. Acad. Sci USA, 1998, 95, 2073-2076. |
Gopher, A., et al., “Determination of fructose metabolic pathways in normal and fructose-intolerant children: a 13C NMR study using [U-13C]fructose,” Proc. Natl. Acad. Sci. USA, 1990, 87, 5449-5453. |
Hanvey, J.C., et al., “Antisense and antigene properties of peptide nucleic acids,” Science, 1992, 258, 1481-1485. |
Hiramatsu, K., et al., “Dissemination in Japanese hospitals of strains of staphylococcus aureus heterogeneously resistant to vancomycin,” Lancet, 1997, 350, 1670-1673. |
Hsueh, P., “Persistence of a multidrug-resistant psuedomanas aeruginosa clone in an intensive care burn unit,” J. Clin. Microbiol, 1998, 36(5), 1347-1351. |
Johnson, A.P., “Intermediate vancomycin resistance in staphylococcus aureus: a major threat or a minor inconvenience?,” J. Antimicrob Chemother, 1998, 42, 289-291. |
Knudsen, H., et al., “Antisense properties of duplex-and triplex-forming PNAs,” Nucleic Acids Res., 1996, 24(5), 494-500. |
Lepelletier, D., et al., Escherichia coli: epidemiology and analysis of risk factors for infections caused by resistant strains, Clin. Infect. Dis., 1999, 3, 548-552. |
Lewis, J.G., et al., “A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plamsid DNA,” Proc. Natl. Acad. Sci. USA, 1996, 93, 3176-3181. |
Livermore, D., “Multiresistance and ‘superbugs’,” Commun. Dis. Public Health, 1998, 1(2), 74-78. |
Livermore, D.M., “Acquired carbapenemases,” J. Antimicrob Chemother, 1997, 39, 673-676. |
Mcneeley, D.F., et al., “An investigation of vancomycin-resistanct enterococus faecium within the pediatric service of a large urban medical center,” Pediatr Infect. Dis. J., 1998, 17, 184-188. |
Meyer, O., et al., “cationic lipsomes coated with polyethylene glycol as carriers for oligonucleotides,” J. Biol. Chem., 1998, 273 (25), 15621-15627. |
Nielsen, P.E., et al., “Peptide nucleic acid (:PNA), a DNA mimic with a pseudopeptide backbone,” Chemical Society Reviews, 1997, 73-78. |
Nielsen, P.E., et al., “Sequence-selevtive recognition of DNA by strand displacement with a thymine-substituted polyamide,” Science, 1991, 254, 1497-1500. |
Nyce, J.W., et al., “DNA antisense therapy for asthma in an animal model,” Nature, 997, 385, 721-725. |
Northey, D., et al., “Microbial surveillance in a surgical intensive care unit,” Surg. Gynaecol Obstet., 1974, 140(3), 321-325. |
Pooga, M., et al., “Cell penetrating PNA constructs regulate galanin receptor levels and modifiy pain transmission in vivo,” Nature Biotechnology, 1998, 16, 857-861. |
Porter, E.A., et al., “Non-haemolytic β-amino-acid oligomers,” Nature, 2000, 404, 565. |
Richards, M.J., et al., “Nosocomial infections in medical intensive care units in the United States,” Crt Care Med., 1999, 27 (5), 887-892. |
Vincent, J., et al., “The prvalence of nosocomial infection in intensive care units in Europe,” JAMA, 1995, 274 (8), 639-644. |
Zervos, M., “Vancomycin-resistant enterococcus faecium infections in the ICU and quinupristin/dalfopristin,” New Horizons, 1996, 4(3), 385-392. |